• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大体Borrmann分型作为进展期胃癌患者的一个简单预后指标。

Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer.

作者信息

Li Chen, Oh Sung Jin, Kim Sungsoo, Hyung Woo Jin, Yan Min, Zhu Zheng Gang, Noh Sung Hoon

机构信息

Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Oncology. 2009;77(3-4):197-204. doi: 10.1159/000236018. Epub 2009 Sep 3.

DOI:10.1159/000236018
PMID:19729977
Abstract

BACKGROUND

The purpose of this study was to clarify the clinical significance of macroscopic Borrmann type in advanced gastric cancer.

METHODS

From 1987 to 2001, we retrospectively studied the clinicopathological features and prognoses of 3,966 patients with advanced gastric cancer according to the macroscopic classification of Borrmann type.

RESULTS

Multivariate analysis showed that gender, Borrmann type and depth of invasion were all associated with the status of nodal involvement. There were statistically significant differences in overall survival among patients with Borrmann type I and II tumors, Borrmann type III tumors, and Borrmann type IV tumors according to depth of invasion (pT) and nodal involvement (pN), except in pN3 tumors. Borrmann type was an independent prognostic factor in patients with advanced gastric cancer. Furthermore, the 5-year survival rates of patients with Borrmann type III and type IV tumors after curative resection were 62.0 and 51.2%, respectively; this was significantly higher than after noncurative resection (17.8 and 18.0%, respectively).

CONCLUSION

Macroscopic Borrmann type is a simple and valuable predictor for lymph node metastasis and survival in advanced gastric cancer patients.

摘要

背景

本研究旨在阐明进展期胃癌中Borrmann大体分型的临床意义。

方法

1987年至2001年,我们根据Borrmann大体分型对3966例进展期胃癌患者的临床病理特征及预后进行了回顾性研究。

结果

多因素分析显示,性别、Borrmann分型及浸润深度均与淋巴结受累情况相关。根据浸润深度(pT)和淋巴结受累情况(pN),Borrmann I型和II型肿瘤患者、Borrmann III型肿瘤患者以及Borrmann IV型肿瘤患者的总生存率存在统计学显著差异,但pN3肿瘤患者除外。Borrmann分型是进展期胃癌患者的独立预后因素。此外,Borrmann III型和IV型肿瘤患者根治性切除后的5年生存率分别为62.0%和51.2%;这显著高于非根治性切除后的生存率(分别为17.8%和18.0%)。

结论

Borrmann大体分型是进展期胃癌患者淋巴结转移及生存情况的一个简单且有价值的预测指标。

相似文献

1
Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer.大体Borrmann分型作为进展期胃癌患者的一个简单预后指标。
Oncology. 2009;77(3-4):197-204. doi: 10.1159/000236018. Epub 2009 Sep 3.
2
Adenocarcinoma in the middle third of the stomach--an evaluation for the prognostic significance of clinicopathological features.胃中三分之一腺癌——临床病理特征预后意义的评估
Hepatogastroenterology. 1997 Sep-Oct;44(17):1488-94.
3
Lymph node metastasis as a single predictor in patients with Borrmann type I gastric cancer.淋巴结转移作为Borrmann I型胃癌患者的单一预测指标。
Hepatogastroenterology. 2007 Apr-May;54(75):981-4.
4
Clinicopathologic prognostic factors in patients with Borrmann type 4 gastric cancer: univariate and multivariate analyses.Borrmann 4型胃癌患者的临床病理预后因素:单因素和多因素分析
Ups J Med Sci. 2000;105(3):227-34.
5
Regional lymph node metastasis as a predictor of peritoneal carcinomatosis in patients with Borrmann type IV gastric carcinoma.区域淋巴结转移作为Borrmann IV型胃癌患者腹膜种植转移的预测指标
Am J Gastroenterol. 1999 Feb;94(2):434-7. doi: 10.1111/j.1572-0241.1999.873_b.x.
6
Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma.腹膜种植转移和淋巴结转移是Borrmann Ⅳ型胃癌患者的预后指标。
Hepatogastroenterology. 2002 May-Jun;49(45):874-7.
7
Prognostic factors of gastric cancer tumours of less than 2 cm in diameter: rationale for limited surgery.直径小于2厘米的胃癌肿瘤的预后因素:有限手术的理论依据
Eur J Surg Oncol. 2002 Apr;28(3):209-13. doi: 10.1053/ejso.2001.1178.
8
Is tumor size a prognostic indicator for gastric carcinoma?肿瘤大小是胃癌的预后指标吗?
Anticancer Res. 2002 Nov-Dec;22(6B):3673-7.
9
[Metastasis rates of lymph nodes and distribution in advanced gastric cancer and its clinical significance].[进展期胃癌淋巴结转移率及分布情况及其临床意义]
Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Nov;9(6):506-9.
10
Gastric carcinoma invading muscularis propria and macroscopic appearance.侵犯固有肌层的胃癌及大体外观。
Eur J Surg Oncol. 1992 Apr;18(2):131-4.

引用本文的文献

1
Laparoscopic gastrectomy reduced peritoneal recurrence in Borrmann type IV gastric cancer: a retrospective cohort study with propensity score matching.腹腔镜胃切除术降低Borrmann IV型胃癌的腹膜复发:一项倾向评分匹配的回顾性队列研究
Surg Endosc. 2025 May 27. doi: 10.1007/s00464-025-11791-5.
2
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902).多西他赛、奥沙利铂和S-1新辅助治疗大型3型或4型胃癌患者:一项多中心II期研究(OGSG1902)的短期结果
Gastric Cancer. 2025 Mar 31. doi: 10.1007/s10120-025-01608-8.
3
Chemotherapy Options for Locally Advanced Gastric Cancer: A Review.
局部进展期胃癌的化疗方案综述
Cancers (Basel). 2025 Feb 26;17(5):809. doi: 10.3390/cancers17050809.
4
Weighted Gene Coexpression Network Analysis Identifies Neutrophil-Related Molecular Subtypes and Their Clinical Significance in Gastric Cancer.加权基因共表达网络分析鉴定胃癌中与中性粒细胞相关的分子亚型及其临床意义。
Cancer Manag Res. 2025 Feb 28;17:397-418. doi: 10.2147/CMAR.S500215. eCollection 2025.
5
Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S-1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205).S-1与顺铂新辅助放化疗用于临床可切除的4型或大型3型胃癌患者的I/II期研究(OGSG1205)
Ann Surg Oncol. 2025 Apr;32(4):2651-2661. doi: 10.1245/s10434-024-16845-x. Epub 2025 Jan 15.
6
Sedated and unsedated gastroscopy has no influence on the outcomes of patients with gastric cancer: a retrospective study.镇静与非镇静胃镜检查对胃癌患者的预后无影响:一项回顾性研究
BMC Cancer. 2025 Jan 6;25(1):13. doi: 10.1186/s12885-024-13413-0.
7
Phase I study of neoadjuvant chemoradiotherapy with S-1 for clinically resectable type 4 or large type 3 gastric cancer in elderly patients aged 75 years and older (OGSG1303).S-1新辅助放化疗用于75岁及以上老年患者临床可切除的4型或大3型胃癌的I期研究(OGSG1303)
Med Oncol. 2024 Dec 19;42(1):31. doi: 10.1007/s12032-024-02583-3.
8
Exploring the therapeutic potential of diterpenes in gastric cancer: Mechanisms, efficacy, and clinical prospects.探索二萜类化合物在胃癌治疗中的潜力:作用机制、疗效及临床前景
Biomol Biomed. 2024 Dec 11;25(1):1-15. doi: 10.17305/bb.2024.10887.
9
Comprehensive survival nomograms for locally advanced gastric cancer: a large population-based real-world study.局部晚期胃癌的综合生存列线图:一项基于大人群的真实世界研究。
Transl Cancer Res. 2023 Nov 30;12(11):2989-3006. doi: 10.21037/tcr-22-1255. Epub 2023 Nov 24.
10
Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy.术前治疗时代胃腺癌中阳性手术切缘的临床影响。
Ann Surg Oncol. 2023 Aug;30(8):4936-4945. doi: 10.1245/s10434-023-13495-3. Epub 2023 Apr 27.